Mylab Discovery Solutions has launched MyNeoShield, a patent-pending Point-of-Care Device for Newborn Screening (NBS) in the United States.

It provides findings in just 4 hours, allowing for the prompt diagnosis and treatment of health concerns. This is especially advantageous for smaller healthcare institutions such as clinics and nursing homes, since it eliminates the need for expensive equipment and resources.

Hasmukh Rawal, Co-founder & Managing Director of Mylab, expressed his enthusiasm for this development, said,

“At Mylab, we are deeply committed to advancing healthcare through innovation and accessibility. Our Point-of-Care Device for New-born Screening is a testament to that commitment. By making screening faster and more accessible, we aim to save lives and ensure that every child has the opportunity for a healthy and promising future.”

This device is set to be available commercially from November. The company plans to take the device to global markets with its partners.